20 citations
,
October 2018 in “Clinical Drug Investigation” This study observed that men receiving dutasteride for benign prostatic hyperplasia did not show significant differences in neuropsychological assessments compared to a control group not on dutasteride.
November 2005 in “The Journal of Urology” This paper discusses the effect of dutasteride on prostate cancer detection in men with benign prostatic hyperplasia but provides no new clinical results.
11 citations
,
April 2018 in “Journal of Dermatology” In a randomized study, men treated with dutasteride for androgenetic alopecia experienced sexual adverse events at twice the rate of those on placebo during 24 weeks, but these events were mild, moderate, and resolved after treatment.
7 citations
,
December 2017 in “Journal of the European Academy of Dermatology and Venereology” This study found that dutasteride use is associated with increased reports of sexual dysfunction, based on data from the U.S. Food and Drug Administration Adverse Event Reporting System.
3 citations
,
March 2005 in “The Journal of urology/The journal of urology” This letter to the editor addresses corrections related to an earlier study on the effect of the dual 5α-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer, but reports no new findings.